Direct comparison of tumor tissue-based approach vs. plasma-based ctDNA testing has shown concordance in detecting APC, TP53, KRAS, NRAS, and BRAF mutations in treating naïve and non-anti-EGFR-treated cohorts of colorectal cancer [117]. This evidence concerns the gene KRAS and neoplasm.